Although the AS04 adjuvant system is adequate for the bivalent HPV-16/18 vaccine, next-generation polyvalent vaccines may require the use of other adjuvant systems or technologies. The two studies (NCT00231413 and NCT00478621) were funded by GlaxoSmithKline Biologicals SA, which was involved in all stages of the study/project conduct and data analysis (study design; collection, analysis, and interpretation of data; writing of the report) in collaboration with all investigators. The authors were responsible for the decision to submit the manuscript for publication. Only authors were eligible to approve the article for submission to the journal of their choice. The lead author together with
the sponsor wrote the first draft of the manuscript with the support of a professional medical
writer and publication manager working on behalf of the sponsor. All authors contributed to the development U0126 solubility dmso of subsequent drafts, with the writing and editorial assistance of the sponsor. No honorarium, grant, or other form of payment was given to any of the authors to produce the manuscript. GlaxoSmithKline SP600125 nmr Biologicals SA took in charge all costs associated with the development and publishing of the present publication. We thank study participants and their families. We also thank investigators and co-investigators who are not named as authors (Dan Henry, Foothill Family Clinic, Salt Lake City, UT, USA; Kenneth Cohen, New West Physicians, Golden, CO, USA; Corinne Vandermeulen and Willy Poppe, Universitair Ziekenhuis Leuven, Leuven, Belgium; Isabel Leroux-Roels, Sheron Forgus, Fien De
Boever and Anne Depluverez, Center for Vaccinology, Ghent; Froukje Kafeja and Annick Hens, Universiteit Antwerpen); statistical, clinical study and laboratory support at GlaxoSmithKline (-)-p-Bromotetramisole Oxalate Biologicals SA (Toufik Zahaf, Bart Spiessens, Antonia Volny-Luraghi, Susan Wieting, Nele Martens, Sylviane Poncelet, Nadine Pépin, Michelle Derbyshire, Mercedes Lojo-Suarez, Annelies Vanneuville, Inge Delmotte, Christopher M. Pollitt, Olivier Godeaux, Anne Schuind, Carys Calvert, Patrizia Izurieta, Geneviève Meiers, Fernanda Tavares, Nicolas Lecrenier, Nathalie Houard, Dimitrie Gregoire, Valérie Wansart, Dominique Gilson, Stephanie Maerlan, Valérie Xhenseval, Caroline Hervé, Michel Janssens, Alexandre Smirnoff, Dinis Fernandes-Ferreira, Luc Franssen, Michael Mestre, Murielle Carton, Olivier Jauniaux, Pierre Libert, Samira Hadji, Sarah Charpentier, Valérie Mohy, Zineb Soussi); Julie Taylor (Peak Biomedical Ltd, UK) for writing assistance, and Dirk Saerens (Keyrus Biopharma, Belgium) for editorial assistance and manuscript coordination, on behalf of GlaxoSmithKline Biologicals SA, Wavre, Belgium. Conflict of interest: All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf and declare: P.V.D.